Literature DB >> 17298238

Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.

Kathlyn Santos1, David A L Simon, Erin Conway, William J Bowers, Soumya Mitra, Thomas H Foster, Amit Lugade, Edith M Lord, Howard J Federoff, Stephen Dewhurst, John G Frelinger.   

Abstract

There is great interest in developing new immunization vectors. Helper virus-free herpes amplicons, plasmid-based vectors that encode no viral gene products and have an extremely large coding capacity, are attractive viral vaccine candidates for expressing recombinant proteins in vivo for immunization. Earlier studies in mice, using amplicons encoding the gp120 protein of human immunodeficiency virus (HIV), resulted in strikingly robust cellular immune responses as measured by cytotoxicity and interferon gamma enzyme-linked immunospot assays. To begin to understand how such vectors function in vivo to generate an immune response, we used amplicons encoding reporter constructs including green fluorescent protein (GFP) and luciferase to examine the duration of expression after administration to mice. Luciferase expression, measured with the IVIS system from Xenogen/Caliper Life Sciences (Hopkinton, MA) and by enzymatic assays of tissue extracts, revealed that expression after injection of the HSVluc amplicons peaked earlier than 24 hr after injection into mice. HSVegfp injection resulted in peak accumulation of GFP 24 hr after administration in vivo. Thus, both reporter genes revealed a rather rapid and robust expression pattern of short duration. The short period of expression appears in part to be due to gene silencing. Examination of the cells transduced by amplicons encoding GFP and human B7.1 suggested that the amplicons transduce a variety of cells, including professional antigen-presenting cells. From this and previous work, we conclude that amplicons may engender a potent immune response by directly transducing dendritic cells as well as by cross-priming of antigen produced by other transduced host cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298238     DOI: 10.1089/hum.2006.082

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

Review 1.  Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.

Authors:  Suresh de Silva; William J Bowers
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

2.  HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.

Authors:  Andrea S Laimbacher; Laura E Esteban; Alejandro A Castello; Juan C Abdusetir Cerfoglio; Marcelo H Argüelles; Graciela Glikmann; Alejandra D'Antuono; Nora Mattion; Mabel Berois; Juan Arbiza; Monika Hilbe; Elisabeth M Schraner; Michael Seyffert; Christiane Dresch; Alberto L Epstein; Mathias Ackermann; Cornel Fraefel
Journal:  Mol Ther       Date:  2012-06-19       Impact factor: 11.454

3.  Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.

Authors:  Maria E Frazer; Jennifer E Hughes; Michael A Mastrangelo; Jennifer L Tibbens; Howard J Federoff; William J Bowers
Journal:  Mol Ther       Date:  2008-03-11       Impact factor: 11.454

4.  Constitutive and Inducible Innate Responses in Cells Infected by HSV-1-Derived Amplicon Vectors.

Authors:  Eliza Tsitoura; Alberto L Epstein
Journal:  Open Virol J       Date:  2010-06-18

5.  ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression.

Authors:  Masataka Suzuki; Kazue Kasai; Akihiro Ohtsuki; Jakub Godlewski; Michal O Nowicki; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 6.  Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Authors:  Kathleen A Maguire-Zeiss; Howard J Federoff
Journal:  J Neuroimmune Pharmacol       Date:  2008-10-18       Impact factor: 4.147

7.  HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime.

Authors:  Cindy M P Duke; Casey A Maguire; Michael C Keefer; Howard J Federoff; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

8.  Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0.

Authors:  Clark A Burris; Suresh de Silva; Wade C Narrow; Ann E Casey; Louis T Lotta; Howard J Federoff; William J Bowers
Journal:  J Gene Med       Date:  2008-02       Impact factor: 4.565

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.